Varian Medical Systems, Inc. is the leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The Company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection.
The Halcyon system is Varian’s newest cancer treatment device, engineered to simplify and enhance virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT). Halcyon combines fast volumetric imaging and dose delivery with the power of Eclipse treatment planning system in a transformative platform.
Company Growth (employees)
Varian Medical Systems was founded in 1948 and is headquartered in Palo Alto, US
Varian Medical Systems Office Locations
Varian Medical Systems has an office in Palo Alto
Palo Alto, US (HQ)
3100 Hansen Way
Varian Medical Systems Data and Metrics
Varian Medical Systems Financial Metrics
Varian Medical Systems's revenue was reported to be $3.2 b in FY, 2016 which is a 4% increase from the previous period.
USD
Revenue (FY, 2016) | 3.2 b |
Revenue growth (FY, 2015 - FY, 2016), % | 4% |
Gross profit (FY, 2016) | 1.4 b |
Gross profit margin (FY, 2016), % | 42% |
Net income (FY, 2016) | 402.7 m |
EBIT (FY, 2016) | 550.8 m |
Market capitalization (21-Jul-2017) | 9.8 b |
Cash (30-Sep-2016) | 843.5 m |
EV | 9.6 b |
Varian Medical Systems's current market capitalization is $9.8 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 2.9 b | 3 b | 3.1 b | 3.2 b |
Revenue growth, % | 4% | 2% | 4% | |
Cost of goods sold | 1.7 b | 1.7 b | 1.8 b | 1.9 b |
Gross profit | 1.2 b | 1.3 b | 1.3 b | 1.4 b |
Gross profit Margin, % | 42% | 43% | 41% | 42% |
R&D expense | 208.2 m | 234.8 m | 245.2 m | 253.5 m |
General and administrative expense | 432.6 m | 470.6 m | 488.5 m | 540.1 m |
Operating expense total | 640.8 m | 730.5 m | 733.7 m | 810.5 m |
EBIT | 608.9 m | 571.2 m | 549 m | 550.8 m |
EBIT margin, % | 21% | 19% | 18% | 17% |
Interest expense | (4.1 m) | (7.2 m) | (7.9 m) | (11.8 m) |
Interest income | 7.3 m | 10.5 m | 13.6 m | 17.4 m |
Pre tax profit | 612.1 m | 574.5 m | 554.7 m | 556.4 m |
Net Income | 438.2 m | 403.7 m | 412 m | 402.7 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 1.1 b | 849.3 m | 845.5 m | 843.5 m |
Accounts Receivable | 4.4 m | 1.3 m | ||
Inventories | 535.2 m | 572.3 m | 612.6 m | 639.7 m |
Current Assets | 2.7 b | 2.5 b | 2.5 b | 2.6 b |
PP&E | 315.3 m | 338 m | 379.2 m | 379.2 m |
Goodwill | 225.3 m | 240.6 m | 283.5 m | 294.7 m |
Total Assets | 3.5 b | 3.4 b | 3.6 b | 3.8 b |
Accounts Payable | 194.3 m | 187.4 m | 202.9 m | 201.1 m |
Total Debt | 617.1 m | |||
Current Liabilities | 1.2 b | 1.2 b | 1.4 b | 1.6 b |
Total Liabilities | 2.1 b | |||
Additional Paid-in Capital | 637.1 m | 642.8 m | 682.2 m | 678.6 m |
Retained Earnings | 1 b | 931.2 m | 1 b | 1.1 b |
Total Equity | 1.6 b | 1.7 b | 1.7 b | |
Debt to Equity Ratio | 0.4 x | |||
Debt to Assets Ratio | 0.2 x | |||
Financial Leverage | 2.1 x | 2.1 x | 2.2 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 438.2 m | 403.7 m | 412 m | 402.7 m |
Depreciation and Amortization | 62.9 m | 62.5 m | 68.5 m | 64.2 m |
Accounts Receivable | (43.3 m) | (74.5 m) | (79.4 m) | (168.3 m) |
Inventories | (76.4 m) | (43.3 m) | (41.6 m) | (27.7 m) |
Accounts Payable | 7.8 m | 2 m | 6.5 m | 9.7 m |
Cash From Operating Activities | 455.2 m | 449 m | 469.6 m | 356.3 m |
Purchases of PP&E | (76.3 m) | (89.6 m) | (91.4 m) | (80.4 m) |
Cash From Investing Activities | (96.3 m) | (133.1 m) | (210.9 m) | (109.2 m) |
Cash From Financing Activities | 51.6 m | (595.5 m) | (276.7 m) | (245.8 m) |
| USD | Y, 2016 |
|---|---|
EV/EBIT | 17.4 x |
EV/CFO | 26.9 x |
Revenue/Employee | 429 k |
Debt/Equity | 0.4 x |
Debt/Assets | 0.2 x |
Financial Leverage | 2.2 x |
Varian Medical Systems Market Value History
Varian Medical Systems Median Salaries
Source: 202 public H-1B filings from Varian Medical Systems
